Patents by Inventor Xiong Cai

Xiong Cai has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY
    Publication number: 20170362251
    Abstract: The instant application relates to deazapurines, thienopyrimidines and furopyrimidines with zinc-binding moiety based derivatives and their use in the treatment of phosphoinositide 3-kinase related diseases and disorders such as cancer. The instant application further relates to the treatment of histone deacetylase related disorders and diseases related to both histone deacetylase and phosphoinositide 3-kinase.
    Type: Application
    Filed: June 29, 2017
    Publication date: December 21, 2017
    Inventors: Xiong Cai, Haixiao Zhai, Chengjung Lai, Chenggeng Qian
  • HEDGEHOG ANTAGONISTS HAVING ZINC BINDING MOIETIES
    Publication number: 20170349573
    Abstract: The present invention provides compounds which antagonize hedgehog signaling and inhibit HDAC activity. The compounds can be used in methods of treating proliferative diseases and disorders such as cancer.
    Type: Application
    Filed: June 21, 2017
    Publication date: December 7, 2017
    Inventors: Xiong Cai, Changgeng Qian, Haixiao Zhai
  • PHOSPHOINOSITIDE 3-KINASE INHIBITOR WITH A ZINC BINDING MOIETY
    Publication number: 20170304279
    Abstract: The invention provides a compound of Formula I, Pharmaceutical compositions comprising such compounds and the use of such compounds in the treatment of phosphoinositide 3-kinase related diseases and disorders such as cancer. The instant application further relates to the treatment of histone deacetylase related disorders and diseases related to both histone deacetylase and phosphoinositide 3-kinase.
    Type: Application
    Filed: April 25, 2017
    Publication date: October 26, 2017
    Inventors: Xiong Cai, Haixiao Zhai, Chengjung Lai, Chenggeng Qian
  • FUSED AMINO PYRIDINE AS HSP90 INHIBITORS
    Publication number: 20170267674
    Abstract: The present invention relates to HSP90 inhibitors containing fused amino pyridine core that are useful as inhibitors of HSP90 and their use in the treatment of HSP90 related diseases and disorders such as cancer, an autoimmune disease, or a neurodegenerative disease.
    Type: Application
    Filed: March 30, 2017
    Publication date: September 21, 2017
    Inventors: Xiong Cai, Changgeng Qian, Haixiao Zhai
  • Phosphoinositide 3-kinase inhibitors with a zinc binding moiety
    Patent number: 9725461
    Abstract: The instant application relates to deazapurines, thienopyrimidines and furopyrimidines with zinc-binding moiety based derivatives and their use in the treatment of phosphoinositide 3-kinase related diseases and disorders such as cancer. The instant application further relates to the treatment of histone deacetylase related disorders and diseases related to both histone deacetylase and phosphoinositide 3-kinase.
    Type: Grant
    Filed: November 12, 2014
    Date of Patent: August 8, 2017
    Assignee: Curis, Inc.
    Inventors: Xiong Cai, Haixaio Zhai, Chengjung Lai, Changgeng Qian
  • Hedgehog antagonists having zinc binding moieties
    Patent number: 9708299
    Abstract: The present invention provides compounds which antagonize hedgehog signaling and inhibit HDAC activity. The compounds can be used in methods of treating proliferative diseases and disorders such as cancer.
    Type: Grant
    Filed: July 1, 2013
    Date of Patent: July 18, 2017
    Assignees: Genentech, Inc., Curis, Inc.
    Inventors: Xiong Cai, Changgeng Qian, Haixiao Zhai
  • Phosphoinositide 3-kinase inhibitor with a zinc binding moiety
    Patent number: 9657032
    Abstract: The invention provides a compound of Formula I, Pharmaceutical compositions comprising such compounds and the use of such compounds in the treatment of phosphoinositide 3-kinase related diseases and disorders such as cancer. The instant application further relates to the the treatment of histone deacetylase related disorders and diseases related to both histone deacetylase and phosphoinositide 3-kinase.
    Type: Grant
    Filed: December 28, 2015
    Date of Patent: May 23, 2017
    Assignee: Curis, Inc.
    Inventors: Xiong Cai, Haixiao Zhai, Chengjung Lai, Chenggeng Qian, Rudi Bao
  • Fused amino pyridine as HSP90 inhibitors
    Patent number: 9630965
    Abstract: The present invention relates to HSP90 inhibitors containing fused amino pyridine core that are useful as inhibitors of HSP90 and their use in the treatment of HSP90 related diseases and disorders such as cancer, an autoimmune disease, or a neurodegenerative disease.
    Type: Grant
    Filed: July 1, 2016
    Date of Patent: April 25, 2017
    Assignee: Curis, Inc.
    Inventors: Xiong Cai, Changgeng Qian, Haixiao Zhai
  • COMPOUNDS AND THERAPEUTICAL USE THEREOF
    Publication number: 20170050937
    Abstract: Disclosed are 4-arylamino-quinazolines and analogs thereof effective as activators of caspases and inducers of apoptosis. The compounds of this invention are useful in the treatment of a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.
    Type: Application
    Filed: March 25, 2016
    Publication date: February 23, 2017
    Inventors: Sui Xiong Cai, Nilantha Sudath Sirisoma, Azra Pervin, John A. Drewe, Shailaja Kasibhatla, Songchun Jiang, Hong Zhang, Chris Pleiman, Vijay Baichwal, John Manfredi, Leena Bhoite
  • FUSED AMINO PYRIDINE AS HSP90 INHIBITORS
    Publication number: 20170002002
    Abstract: The present invention relates to HSP90 inhibitors containing fused amino pyridine core that are useful as inhibitors of HSP90 and their use in the treatment of HSP90 related diseases and disorders such as cancer, an autoimmune disease, or a neurodegenerative disease.
    Type: Application
    Filed: July 1, 2016
    Publication date: January 5, 2017
    Inventors: Xiong Cai, Changgeng Qian, Haixiao Zhai
  • Process of manufacturing rain waterproof breathable fabric
    Publication number: 20160319481
    Abstract: A rain-test resistant, high-vapor-permeable, water-repellent and water-resistant manufacturing process for making such fabrics is provided. It is used in the dyeing and finishing process of fabric in which the fabric is treated with the treatment roller, knife roller, and spray methods. These combined methods can coat water-repellent agent on the fabric and form a very thin film on the fabric. This protective film on the fabric enhances the wash resistance of the fabric while it will not adversely affect the water repellence and water resistance of the fabric. Moreover, this technique of forming a very thin water-repellent film on the fabric rules out the conventional method with which the water-repellent agent dipped within the fabric structure is easily washed out with regular laundry of the fabric due to the lesser amount of the agent being attached onto the fabric.
    Type: Application
    Filed: July 15, 2016
    Publication date: November 3, 2016
    Inventors: Qiu-Xiong Cai, Feng-Ying Tian, Jia-Yong Xie
  • Fused Amino Pyridines for the Treatment of Lung Cancer
    Publication number: 20160317508
    Abstract: The present invention relates to the use of compounds with fused amino pyridine core for the treatment of malignancies associated with brain and lung. The oral administration of compounds of the instant application results in effective brain penetration and provides for non-intrusive treatment of brain and lung tumors.
    Type: Application
    Filed: May 4, 2016
    Publication date: November 3, 2016
    Inventors: Xiong Cai, Changgeng Qian
  • 1-(Arylmethyl)quinazoline-2,4(1H,3H)-Diones as PARP Inhibitors and the Use Thereof
    Publication number: 20160237070
    Abstract: Disclosed are 1-(arylmethyl)quinazoline-2,4(1H,3H)-diones represented by the Formula (I): wherein Ar, R1-R6 are defined herein. Compounds having Formula (I) are PARP inhibitors. Therefore, compounds of the invention may be used to treat clinical conditions that are responsive to the inhibition of PARP activity.
    Type: Application
    Filed: February 12, 2016
    Publication date: August 18, 2016
    Inventors: Sui Xiong CAI, Ye TIAN, Haijun DONG, Qingbing XU, Lizhen WU, Lijun LIU, Yangzhen JIANG, Qingli BAO, Guoxiang WANG, Feng YIN, Chengyun GU, Xiuhua HU, Xiaozhu WANG, Sishun KANG, Shengzhi CHEN
  • Fused amino pyridine as HSP90 inhibitors
    Patent number: 9402832
    Abstract: The present invention relates to HSP90 inhibitors containing fused amino pyridine core that are useful as inhibitors of HSP90 and their use in the treatment of HSP90 related diseases and disorders such as cancer, an autoimmune disease, or a neurodegenerative disease.
    Type: Grant
    Filed: April 8, 2015
    Date of Patent: August 2, 2016
    Assignee: Curis, Inc.
    Inventors: Xiong Cai, Changgeng Qian, Haixiao Zhai
  • PHOSPHOINOSITIDE 3-KINASE INHIBITOR WITH A ZINC BINDING MOIETY
    Publication number: 20160185796
    Abstract: The invention provides a compound of Formula I, Pharmaceutical compositions comprising such compounds and the use of such compounds in the treatment of phosphoinositide 3-kinase related diseases and disorders such as cancer. The instant application further relates to the the treatment of histone deacetylase related disorders and diseases related to both histone deacetylase and phosphoinositide 3-kinase.
    Type: Application
    Filed: December 28, 2015
    Publication date: June 30, 2016
    Inventors: Xiong Cai, Haixiao Zhai, Chengjung Lai, Chenggeng Qian, Rudi Bao
  • 1-(Arylmethyl)quinazoline-2,4(1,3)-diones as PARP inhibitors and the use thereof
    Patent number: 9290460
    Abstract: Disclosed are 1-(arylmethyl)quinazoline-2,4(1H,3H)-diones thereof, represented by the Formula (I) wherein Ar, R1-R6 are defined herein. Compounds having Formula (I) are PARP inhibitors. Therefore, compounds of the invention may be used to treat clinical conditions that are responsive to the inhibition of PARP activity.
    Type: Grant
    Filed: March 31, 2012
    Date of Patent: March 22, 2016
    Assignee: IMPACT THERAPEUTICS, INC.
    Inventors: Sui Xiong Cai, Ye Edward Tian, Xiuhua Hu
  • FUSED AMINO PYRIDINE AS HSP90 INHIBITORS
    Publication number: 20160058742
    Abstract: The present invention relates to HSP90 inhibitors containing fused amino pyridine core that are useful as inhibitors of HSP90 and their use in the treatment of HSP90 related diseases and disorders such as cancer, an autoimmune disease, or a neurodegenerative disease.
    Type: Application
    Filed: April 8, 2015
    Publication date: March 3, 2016
    Inventors: Xiong Cai, Changgeng Qian, Haixiao Zhai
  • Phosphoinositide 3-kinase inhibitor with a zinc binding moiety
    Patent number: 9249156
    Abstract: The invention provides a compound of Formula I, Pharmaceutical compositions comprising such compounds and the use of such compounds in the treatment of phosphoinositide 3-kinase related diseases and disorders such as cancer. The instant application further relates to the treatment of histone deacetylase related disorders and diseases related to both histone deacetylase and phosphoinositide 3-kinase.
    Type: Grant
    Filed: March 5, 2014
    Date of Patent: February 2, 2016
    Assignee: Curis, Inc.
    Inventors: Xiong Cai, Haixiao Zhai, Chengjung Lai, Changgeng Qian, Rudi Bao
  • Tyrosine kinase inhibitors containing a zinc binding moiety
    Patent number: 9169244
    Abstract: The present invention relates to tyrosine kinase inhibitors that contain a zinc-binding moiety and their use in the treatment of tyrosine related diseases and disorders such as cancer. The said derivatives may further act as HDAC inhibitors.
    Type: Grant
    Filed: March 18, 2013
    Date of Patent: October 27, 2015
    Assignee: Curis, Inc.
    Inventors: Xiong Cai, Changgeng Qian, Stephen Gould, Haixiao Zhai
  • QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY
    Publication number: 20150284340
    Abstract: The present invention relates to quinazoline containing zinc-binding moiety based derivatives of Formula (IV) below: These compounds have enhanced and unexpected properties as inhibitors of epidermal growth factor receptor tyrosine kinase (EGFR-TK) and are useful in the treatment of EGFR-TK related diseases and disorders such as cancer. These compounds may further act as HDAC inhibitors.
    Type: Application
    Filed: April 15, 2015
    Publication date: October 8, 2015
    Inventors: Changgeng Qian, Xiong Cai, Stephen Gould, Haixiao Zhai